JAGX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
1.2M
-94.0%
20.3M
+526.6%
3.2M
+4.9%
3.1M
+3.5%
3.0M
Cost of Revenue
1.0M
-11.0%
1.2M
-47.4%
2.2M
+313.5%
532.0K
+0.9%
527.0K
Gross Profit
194.0K
-99.0%
19.1M
+1746.8%
1.0M
-59.4%
2.6M
+4.0%
2.5M
Operating Expenses
7.8M
-12.8%
8.9M
-58.4%
21.5M
+119.4%
9.8M
-6.4%
10.5M
R&D
3.3M
-15.1%
3.9M
-72.6%
14.3M
+291.3%
3.7M
+12.0%
3.3M
SG&A
4.5M
-11.0%
5.0M
-30.2%
7.2M
+16.8%
6.1M
-14.8%
7.2M
Operating Income
-7597000
-174.6%
10.2M
+149.8%
-20442000
-182.4%
-7238000
+9.6%
-8007000
EBITDA
-7124000
-166.9%
10.7M
+153.4%
-19965000
-195.4%
-6759000
+10.2%
-7529000
Net Income
-12802000
-246.8%
8.7M
+137.6%
-23193000
-140.4%
-9648000
+8.6%
-10560000
EPS (Basic)
$-15.70
-15.4%
$-13.60
+87.0%
$-104.52
+42.5%
$-181.65
+49.4%
$-358.94
EPS (Diluted)
$-15.70
-15.4%
$-13.60
+87.0%
$-104.52
+42.5%
$-181.65
+49.4%
$-358.94
Shares (Diluted)
809.1K
+56.9%
515.8K
+132.4%
222.0K
+324.3%
52.3K
+80.4%
29.0K
Jaguar Health (JAGX) โ€” Financials